Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

CDK4/6抑制剂治疗HR阳性/HER2阴性晚期乳腺癌中HER2低表达状态的预后意义

阅读：2
作者：Zattarin,Emma,Presti,Daniele,Mariani,Luigi,Sposetti,Caterina,Leporati,Rita,Menichetti,Alice,Corti,Chiara,Benvenuti,Chiara,Fucà,Giovanni,Lobefaro,Riccardo,Ligorio,Francesca,Provenzano,Leonardo,Vingiani,Andrea,Del Vecchio,Marta,Griguolo,Gaia,Sirico,Marianna,Bernocchi,Ottavia,Marra,Antonio,Zagami,Paola,Agostinetto,Elisa,Jacobs,Flavia,Di Mauro,Pierluigi,Esposito,Andrea,Giorgi,Carlo Alberto,Lalli,Luca,Boldrini,Laura,Giacchetti,Pier Paolo Berton,Schianca,Ambra Carnevale,Guarneri,Valentina,Pedersini,Rebecca,Losurdo,Agnese,Zambelli,Alberto,Generali,Daniele,Criscitiello,Carmen,Curigliano,Giuseppe,Pruneri,Giancarlo,de Braud,Filippo,Dieci,Maria Vittoria,Vernieri,Claudio
期刊：NPJ Breast Cancer影响因子：7.600
时间：2023起止号：2023 Apr 17;9(1):27
doi：10.1038/s41523-023-00534-1

Abstract

Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。